Peptide Controls Blood Sugar in People With Congenital Hyperinsulinism, Pilot Study Suggests

ScienceDaily (Aug. 1, 2012) — A pilot study in adolescents and adults has found that an investigational drug shows promise as the first potential medical treatment for children with the severest type of congenital hyperinsulinism, a rare but potentially devastating disease in which gene mutations cause insulin levels to become dangerously high.




congenital hyperinsulinism

• There is currently no effective medicine for children with the most common and most severe form of hyperinsulinism, 
• this investigational drug, a peptide called exendin-(9-39), controls blood sugar levels in people, a very promising result. 

Journal Reference:

1. Diva D. De Leon. The GLP-1 Receptor Antagonist Exendin-(9-39) Elevates Blood Fasting Glucose Levels in Congenital Hyperinsulinism due to Inactivating Mutations in the ATP-sensitive Potassium Channel.Diabetes, October 2012 DOI: 10.2337/db12-0166